Risk analysis of cardiovascular toxicity in patients with lymphoma treated with CD19 CAR T cells

Risk analysis of cardiovascular toxicity in patients with lymphoma treated with CD19 CAR T cells

Abstract Background Anti-CD19 chimeric antigen receptor (CAR) T cell therapy is a common, yet highly efficient, cellular immunotherapy for lymphoma. However, many recent studies have reported on its cardiovascular (CV) toxicity. This study analyzes the cardiotoxicity of CD19 CAR T cell therapy in th...

Full description

Saved in:
Bibliographic Details
Main Authors: Yang Liu, Xiaoshuang Yuan, Xu Yang, Bo Yang, Guangyang Liu, Xiao Xu, Sanbin Wang, Zhixu He, Feiqing Wang, Yanju Li
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Journal of Translational Medicine
Subjects:
CD19
Chimeric antigen receptor T cells
CAR-T therapy
Lymphoma
Cardiovascular toxicity
Online Access:https://doi.org/10.1186/s12967-024-06035-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12967-024-06035-4

Similar Items